People · Operator
Named in public records as an officer, director or promoter · active 2024–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vizgen, Inc. | — | Biotechnology | Series D+ | $295.1M | $320.2M | 2024 |
Christian Uhrich at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Christian Uhrich on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Keith Crandell | 1 | 11 |
| David Walt | 1 | 6 |
| Andrea Jackson | 1 | 6 |
| Matthew Posard | 1 | 4 |
| Robert Carson | 1 | 3 |
| Philip Gardella | 1 | 2 |
| Marijn E. Dekkers | 1 | 2 |
| Dr. Peidong Wang | 1 | 1 |
| Dr. Philip Gardella | 1 | 1 |
| Dr. Jiang He | 1 | 1 |
| Simona Levi | 1 | 1 |
| Christian Urhich | 1 | 1 |
| Chris Guiffre | 1 | 1 |
| Terry Lo | 1 | 1 |
| Seth Benson | 1 | 1 |
| Matthew E. Posard | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.